Boston Sci hit by Chinese cyber attack; AtriCure gets FDA's blessing for Synergy ablation system;

> Boston Scientific ($BSX) was one of 760 companies targeted Chinese cyber attacks that also affected U.S. government agencies, research universities and Internet providers. Story

> The FDA has OKed AtriCure's ($ATRC) Synergy ablation system for the treatment of atrial fibrillation. Back in October, Canaccord Genuity analyst Jason Mills named AtriCure one of 5 medtech companies that he viewed as potential acquisition targets within the next year or so. AtriCure release

> The first European ophthalmic surgeon has treated patients using OptiMedica's Catalys precision laser system for cataract surgery. The CE mark-approved Catalys combines a femtosecond laser, integrated optical coherence tomography imaging and OptiMedica's pattern scanning technology in an easy-to-use system that brings new levels of precision and accuracy to the cataract procedure. OptiMedica release

> Cerevast Therapeutics, whom we profiled last week after it raised $6.6 million in the initial closing of a Series C round, has won CE mark clearance of its SonoLysis Headframe System, the Clotbust ER. Cerevast release

> You might know it for its contact lenses, but Bausch + Lomb wants you to know it for its pharma offerings, too. Calling pharma his company's "hidden gem," B+L CEO Brent Saunders told PharmaTimes that he is looking to expand his company's pharma ops and wants to become the partner of choice. News

And Finally... In the television series "Star Trek," a handheld medical "tricorder" scans a person's internal organs, offering an instant diagnosis. Today, the Canadian non-profit Grand Challenges is looking to develop that kind of device with help from the Bill and Melinda Gates Foundation. Report